A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates

Dengue viruses (DENVs) cause approximately 390 million cases of DENV infections annually and over 3 billion people worldwide are at risk of infection. No dengue vaccine is currently available nor is there an antiviral therapy for DENV infections. We have developed a tetravalent live-attenuated DENV...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambuel, Yuping, Young, Ginger, Brewoo, Joseph N., Paykel, Joanna, Weisgrau, Kim L., Rakasz, Eva G., Haller, Aurelia A., Royals, Michael, Huang, Claire Y.-H., Capuano, Saverio, Stinchcomb, Dan T., Partidos, Charalambos D., Osorio, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046319/
https://www.ncbi.nlm.nih.gov/pubmed/24926294
http://dx.doi.org/10.3389/fimmu.2014.00263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046319/
https://www.ncbi.nlm.nih.gov/pubmed/24926294
http://dx.doi.org/10.3389/fimmu.2014.00263

Ejemplares similares